Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Enhanced systemic exposure of saquinavir via the concomitant use of curcumin-loaded solid dispersion in rats.

Kim SA, Kim SW, Choi HK, Han HK.

Eur J Pharm Sci. 2013 Aug 16;49(5):800-4. doi: 10.1016/j.ejps.2013.05.029. Epub 2013 Jun 5.

PMID:
23748001
[PubMed - indexed for MEDLINE]
2.

Improved effectiveness of biochanin A as a P-gp inhibitor in solid dispersion.

Han HK, Lee HK.

Pharmazie. 2011 Sep;66(9):710-5.

PMID:
22026129
[PubMed - indexed for MEDLINE]
3.

Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol® HS15 as a carrier.

Seo SW, Han HK, Chun MK, Choi HK.

Int J Pharm. 2012 Mar 15;424(1-2):18-25. doi: 10.1016/j.ijpharm.2011.12.051. Epub 2011 Dec 31.

PMID:
22226878
[PubMed - indexed for MEDLINE]
4.

Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations.

Buchanan CM, Buchanan NL, Edgar KJ, Little JL, Ramsey MG, Ruble KM, Wacher VJ, Wempe MF.

Biomacromolecules. 2008 Jan;9(1):305-13. Epub 2007 Dec 12.

PMID:
18072746
[PubMed - indexed for MEDLINE]
5.

Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.

Lee CK, Ki SH, Choi JS.

Biopharm Drug Dispos. 2011 May;32(4):245-51. doi: 10.1002/bdd.754.

PMID:
21506134
[PubMed - indexed for MEDLINE]
6.

The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.

Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF.

Drug Metab Dispos. 2000 Sep;28(9):1058-62.

PMID:
10950849
[PubMed - indexed for MEDLINE]
Free Article
7.

Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.

Usansky HH, Hu P, Sinko PJ.

Drug Metab Dispos. 2008 May;36(5):863-9. doi: 10.1124/dmd.107.017483. Epub 2008 Feb 6.

PMID:
18256206
[PubMed - indexed for MEDLINE]
Free Article
8.

Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.

Pathak SM, Musmade P, Dengle S, Karthik A, Bhat K, Udupa N.

Eur J Pharm Sci. 2010 Nov 20;41(3-4):440-51. doi: 10.1016/j.ejps.2010.07.013. Epub 2010 Jul 23.

PMID:
20656025
[PubMed - indexed for MEDLINE]
9.

Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, Haefeli WE.

Br J Clin Pharmacol. 2002 Jun;53(6):576-81.

PMID:
12047481
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies.

Dodiya SS, Chavhan SS, Sawant KK, Korde AG.

J Microencapsul. 2011;28(6):515-27. doi: 10.3109/02652048.2011.590612. Epub 2011 Jul 5.

PMID:
21728760
[PubMed - indexed for MEDLINE]
12.

The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.

la Porte CJ, Li Y, Béïque L, Foster BC, Chauhan B, Garber GE, Cameron DW, van Heeswijk RP.

Clin Pharmacol Ther. 2007 Oct;82(4):389-95. Epub 2007 Mar 14.

PMID:
17361121
[PubMed - indexed for MEDLINE]
13.

In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

Shibata N, Gao W, Okamoto H, Kishida T, Yoshikawa Y, Takada K.

J Pharm Pharmacol. 2002 Feb;54(2):221-9.

PMID:
11848286
[PubMed - indexed for MEDLINE]
14.

Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation.

Han HK, Lee BJ, Lee HK.

Int J Pharm. 2011 Aug 30;415(1-2):89-94. doi: 10.1016/j.ijpharm.2011.05.055. Epub 2011 May 27.

PMID:
21645596
[PubMed - indexed for MEDLINE]
15.

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.

J Antimicrob Chemother. 2006 Nov;58(5):1009-16. Epub 2006 Sep 19.

PMID:
16984898
[PubMed - indexed for MEDLINE]
Free Article
16.

Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in-vitro and enhances its bioavailability in rats.

Hirunpanich V, Sato H.

J Pharm Pharmacol. 2006 May;58(5):651-8.

PMID:
16640834
[PubMed - indexed for MEDLINE]
17.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.

Clin Pharmacol Ther. 2005 Dec;78(6):605-18.

PMID:
16338276
[PubMed - indexed for MEDLINE]
18.
19.

Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats.

Shibata N, Kageyama M, Kimura K, Tadano J, Hukushima H, Namiki H, Yoshikawa Y, Takada K.

Biol Pharm Bull. 2004 Feb;27(2):203-9.

PMID:
14758034
[PubMed - indexed for MEDLINE]
Free Article
20.

Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension.

Bravo González RC, Huwyler J, Walter I, Mountfield R, Bittner B.

Int J Pharm. 2002 Oct 1;245(1-2):143-51.

PMID:
12270251
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk